Therapeutic goals in the treatment of Gaucher disease

This publication has 52 references indexed in Scilit:

• Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy
  Blood, 2004
• Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
  Blood, 2004
• Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3
  Neurobiology of Disease, 2003
• Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
  Molecular Genetics and Metabolism, 2003
• Dixon Quantitative Chemical Shift Imaging Is a Sensitive Tool for the Evaluation of Bone Marrow Responses to Individualized Doses of Enzyme Supplementation Therapy in Type 1 Gaucher Disease
  Blood Cells, Molecules, and Diseases, 2001
• Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease
  American Journal of Human Genetics, 2000
• Platelet function abnormalities in Gaucher disease patients
  American Journal of Hematology, 1999
• Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase
  The Journal of Pediatrics, 1996
• Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
  Journal of Clinical Investigation, 1994
• Skeletal Complications of Gaucher Disease
  Medicine, 1985